From knee replacement surgery to liver disease, the GLP-1 "miracle weight loss drug" that has been popular globally since last year seems to be increasingly tested as a "miracle drug," which has caused many sectors hit hard by shocks in the US stock market to fall into chaos successively.

And on Monday, this "storm" clearly rolled towards sleep apnea device manufacturers!

The manufacturer of CPAP (continuous positive airway pressure) ventilator fell by about 11% on Monday, the largest drop in more than 10 months; the manufacturer of sleep apnea implant products fell by 17%, the lowest level since November last year; the supplier of household medical devices selling sleep therapy products fell by 8.1%, the largest drop since December last year... The respiratory ventilator and sleep respiratory equipment manufacturers experienced a sharp decline in the beginning of this week, which is due to the data of GLP-1R/GIPR dual agonist Tirzepatide, the core component of the weight loss drug Zepbound developed by Eli Lilly and Co., which once again shocked the market. The data shows that Eli Lilly's weight loss and diabetes drugs have reduced the severity of obstructive sleep apnea in obese patients.$ResMed (RMD.US)$The manufacturer of CPAP (continuous positive airway pressure) ventilator fell by about 11% on Monday, the largest drop in more than 10 months; the manufacturer of sleep apnea implant products fell by 17%, the lowest level since November last year; the supplier of household medical devices selling sleep therapy products fell by 8.1%, the largest drop since December last year... The respiratory ventilator and sleep respiratory equipment manufacturers experienced a sharp decline in the beginning of this week, which is due to the data of GLP-1R/GIPR dual agonist Tirzepatide, the core component of the weight loss drug Zepbound developed by Eli Lilly and Co., which once again shocked the market. The data shows that Eli Lilly's weight loss and diabetes drugs have reduced the severity of obstructive sleep apnea in obese patients.

The manufacturer of CPAP (continuous positive airway pressure) ventilator fell by about 11% on Monday, the largest drop in more than 10 months; the manufacturer of sleep apnea implant products fell by 17%, the lowest level since November last year; the supplier of household medical devices selling sleep therapy products fell by 8.1%, the largest drop since December last year... The respiratory ventilator and sleep respiratory equipment manufacturers experienced a sharp decline in the beginning of this week, which is due to the data of GLP-1R/GIPR dual agonist Tirzepatide, the core component of the weight loss drug Zepbound developed by Eli Lilly and Co., which once again shocked the market. The data shows that Eli Lilly's weight loss and diabetes drugs have reduced the severity of obstructive sleep apnea in obese patients.$Inspire Medical Systems (INSP.US)$The manufacturer of CPAP (continuous positive airway pressure) ventilator fell by about 11% on Monday, the largest drop in more than 10 months; the manufacturer of sleep apnea implant products fell by 17%, the lowest level since November last year; the supplier of household medical devices selling sleep therapy products fell by 8.1%, the largest drop since December last year... The respiratory ventilator and sleep respiratory equipment manufacturers experienced a sharp decline in the beginning of this week, which is due to the data of GLP-1R/GIPR dual agonist Tirzepatide, the core component of the weight loss drug Zepbound developed by Eli Lilly and Co., which once again shocked the market. The data shows that Eli Lilly's weight loss and diabetes drugs have reduced the severity of obstructive sleep apnea in obese patients.

The manufacturer of CPAP (continuous positive airway pressure) ventilator fell by about 11% on Monday, the largest drop in more than 10 months; the manufacturer of sleep apnea implant products fell by 17%, the lowest level since November last year; the supplier of household medical devices selling sleep therapy products fell by 8.1%, the largest drop since December last year... The respiratory ventilator and sleep respiratory equipment manufacturers experienced a sharp decline in the beginning of this week, which is due to the data of GLP-1R/GIPR dual agonist Tirzepatide, the core component of the weight loss drug Zepbound developed by Eli Lilly and Co., which once again shocked the market. The data shows that Eli Lilly's weight loss and diabetes drugs have reduced the severity of obstructive sleep apnea in obese patients.$AdaptHealth (AHCO.US)$The manufacturer of CPAP (continuous positive airway pressure) ventilator fell by about 11% on Monday, the largest drop in more than 10 months; the manufacturer of sleep apnea implant products fell by 17%, the lowest level since November last year; the supplier of household medical devices selling sleep therapy products fell by 8.1%, the largest drop since December last year... The respiratory ventilator and sleep respiratory equipment manufacturers experienced a sharp decline in the beginning of this week, which is due to the data of GLP-1R/GIPR dual agonist Tirzepatide, the core component of the weight loss drug Zepbound developed by Eli Lilly and Co., which once again shocked the market. The data shows that Eli Lilly's weight loss and diabetes drugs have reduced the severity of obstructive sleep apnea in obese patients.

The manufacturer of CPAP (continuous positive airway pressure) ventilator fell by about 11% on Monday, the largest drop in more than 10 months; the manufacturer of sleep apnea implant products fell by 17%, the lowest level since November last year; the supplier of household medical devices selling sleep therapy products fell by 8.1%, the largest drop since December last year... The respiratory ventilator and sleep respiratory equipment manufacturers experienced a sharp decline in the beginning of this week, which is due to the data of GLP-1R/GIPR dual agonist Tirzepatide, the core component of the weight loss drug Zepbound developed by Eli Lilly and Co., which once again shocked the market. The data shows that Eli Lilly's weight loss and diabetes drugs have reduced the severity of obstructive sleep apnea in obese patients.$Eli Lilly and Co (LLY.US)$The data of GLP-1R/GIPR dual agonist Tirzepatide, the core component of the weight loss drug Zepbound developed by Eli Lilly and Co., once again shocked the market and caused a sharp decline in the respiratory ventilator and sleep respiratory equipment manufacturers at the beginning of this week. The data shows that Eli Lilly's weight loss and diabetes drugs have reduced the severity of obstructive sleep apnea in obese patients.

According to Lilly, Tirzepatide helps solve moderate to severe obstructive sleep apnea, and all major and key secondary endpoints are achieved in clinical trials, and symptoms of over 50% of trial participants are relieved.

Louis Aronne, an obesity expert at Weill Cornell Medical College, said that the results announced at the American Diabetes Association conference are a "groundbreaking trial" in the history of obesity and sleep apnea treatment.

Previously, Lilly's preliminary trial results were released in April, and investors have been waiting for the impact of the full details of the study.

Industry shockwaves.

Stifel analyst Jonathan D. Block believes that the new experimental data released by Lilly obviously brings more questions than answers to device manufacturers.

"Lilly's impressive experimental results further increase the likelihood that sleep experts will include GLP-1 drugs in their treatment regimens," Block wrote in a report.

In fact, in the past year, as more and more data shows the broad impact of weight loss drugs on obesity-related diseases, the pressure on medical device manufacturers has become increasingly greater.

Diabetes device manufacturers, including Insulet and Tandem Diabetes Care, have seen their share prices plummeting due to concerns that GLP-1 drugs will change the industry and cause serious damage to sales. Insulet fell by about 26% in 2023, while Tandem fell by 34%.

Citigroup analysts have downgraded ResMed's rating from buy to neutral and said that the latest results show that "over time, some mild patients may give up CPAP treatment."

At the same time, Truist Securities believes that the risk of shareholding will continue to exist for Inspire. The analyst, Richard Newitter, believes that Inspire may continue to be a focus of speculation and a volatile stock in the next few months until investors are more confident that its equipment utilization rate in 2024 and 2025 can return to a sustainable growth trajectory.

Editor / jayden